There are a growing amount of patients with the psychological trauma symptoms of mental Schizophrenia and disability that are now using complimentary and alternative medicament. There is increased published scientific evidence on their benefits and risks. One such medicament is the supplement Sarcosine said to treat the psychological trauma symptoms of mental Schizophrenia and disability. But what are the benefits and what are the side effects of using Sarcosine supplement for mental Schizophrenia disease?
The natural supplement Sarcosine in clients with Psychological trauma symptoms of mental Schizophrenia and disability has mixed results on the benefits and side effects. But overall side effects are few at the right dosage.
Sarcosine, also known as N-methylglycine, is thought to modulate N-methyl-D-aspartate (NMDA) function through the glycine modulator (to regulate or adjust to a certain degree). Sarcosine has been researched as a putative adjunct therapy (supportive) for a wide variety of disorders ranging from the psychological trauma symptoms of mental Schizophrenia and disability to Psychological trauma symptoms of mental Depression.
The Psychological trauma symptoms of mental Schizophrenia and disability is considered as one of the most serious Psychological trauma symptoms of mental health disorders in the world. It is also still one of the most difficult to understand. The symptoms include delusions and hallucinations (positive symptoms), a flattened mood, the loss of speech or even disorganized speech (negative symptoms). Also, difficulties with attention, memory and decision making (cognitive symptoms).
1-2 people per 10,000 are being diagnosed with the condition of psychological trauma symptoms of mental Schizophrenia disease each year. The Psychological trauma symptoms of mental Depression disease, Psychological trauma and Anxiety, and substance abuse often appear at the same time. There are now multiple studies having been carried out with putative adjunct therapy (support treatment) through the natural supplement Sarcosine and its treatment of Schizophrenia. Multiple studies administered Sarcosine with the usual antipsychotic treatment in clients with acute or stable psychological trauma symptoms of mental Schizophrenia disease. In all the studies and research, the supplement Sarcosine improved the positive, negative, and cognitive symptoms of Schizophrenia more than the antipsychotic drug on its own.
In an experiment of 22 clients with Psychological trauma symptoms of mental Schizophrenia and disability, Sarcosine improved symptoms and was safe. In another on 49 clients, Sarcosine improved the overall cognitive function when supported with benzoate, even if the symptoms did not show improvement. Two further case studies further the role of Sarcosine supplemental in traumatizing Psychological symptoms of mental Schizophrenia: In a patient with the psychological trauma symptoms of mentally Schizophrenia treated with an antipsychotic drug (quetiapine) and an antidepressant drug (citalopram), adjunct treatment of 2 g of Sarcosine daily resolved their negative symptoms in 2 weeks. The client did experience some side effects after a 4 week period. This, was however, resolved once the Sarcosine dose was reduced to just 1 g. Another client with trauma and Schizophrenia with negative symptoms was treated with the antipsychotics and antidepressants: olanzapine and venlafaxine. This was with the inclusion of 2 g of Sarcosine for 10 weeks. Sarcosine improved the client’s low mood, activity, and speech (negative symptoms). However, in another clinical trial of 20 clients, Sarcosine added to clozapine failed to improve the condition over clozapine alone.
Sarcosine (N-methylglycine) is an amino acid that is made in the body from choline (type of B vitamin). The supplement Sarcosine also occurs naturally in the body when choline is changed to glycine (also an amino acid). Sarcosine prevents glycine from being taken back into a brain cell from which it was released. This action potential changes the activity of the receptors by keeping more of the helper molecule glycine ready to aid stimulation of other brain cells via their NMDA (N-methyl-D-aspartate) receptors. This can, among other roles, support memory. In a number of clinical trials, the supplement Sarcosine has been shown to cause less harm to some of the negative conditions of the psychologically traumatizing Schizophrenia disease symptoms. Something that few other compounds or drugs have been shown to do in tests and trials.
Natural sources of Sarcosine include egg yolks, turkey, ham, vegetables, and legumes. These sources provide only minimal amounts so would not be likely to be helpful in the psychological trauma of mental Schizophrenia disease.
The NMDA receptor has been identified to having a role in substance use disorders as well as in traumatic Psychological trauma of mental Schizophrenia and disability. In terms of the psychological trauma symptoms of mental Schizophrenia disease, it has been hypothesized that NMDA receptor hypofunction (decreased or insufficient) plays a role in the mechanism for negative symptoms and cognitive dysfunction in these types of traumatized mental health clients. The NMDA hypofunction may be reversed with increased synaptic glycine being made available.
One collaborative team has developed a novel, non-invasive magnetic resonance spectroscopy (MRS) technique for measuring brain glycine changes that allows them to study glycine Homeostasis. The purpose of this study is to explore the effect of Sarcosine on brain glycine concentrations. It is their theory that the oral supplement Sarcosine, at a dosage of just of 2 grams per day, will be well tolerated and associated with the increasing of brain glycine concentrations. It is their secondary exploratory explanation that: increases in brain glycine will be associated with; behavioural signs of increased NMDA and; dopamine activity. This modulation could have therapeutic potential for psychological mental health issues of hedonic and cognitive function.
A short-term treatment study on NMDA receptor enhancing agents suggests that Sarcosine, superior to D-serine, can benefit clients with the trauma of psychological mental Schizophrenia. These findings indicate that a glycine transporter 1 (GlyT-1) inhibitor may be more effective than NMDA-glycine site agonists for adjunct (complimentary) treatment of the Psychological trauma symptoms of mental Schizophrenia disease. That is, at least during the acute phase. Furthering studies are in need. Treatment response to acute exacerbation of the psychological trauma of mental Schizophrenia disease, Psychosis is incomplete, and patients are frequently left with significant residual symptoms and functional impairments because: 1. The psychological trauma of mental Schizophrenic severe Psychosis can be a degrading of Homeostastic Psychosocial processes and a delay in treatment initiation. Persistent residual symptoms often cause a poor prognosis. 2. It is important to maximize reinforcement of any treatment effects during acute trauma of Schizophrenic psychotic episodes to minimize the residual symptoms and relapse frequency and to cause improvement to the functional outcome. Potentiation (increase in nerve impulses) of N-methyl-D-aspartate (NMDA) receptor mediated neurotransmission has been proposed as a treatment alternative for Schizophrenia Psychosis. 3.Several studies have demonstrated the clinical benefits of treatment for chronic Schizophrenia Psychosis that targets the glycine site of the NMDA receptor (the NMDA-glycine site).
Risperidone. Findings require some confirmation in a side-by-side trial. Although using the supplement Sarcosine as a treatment, it can be beneficial for clients receiving either typical antipsychotic agents or the atypical agent risperidone, the effects of D-serine that activates NMDA in clients taking risperidone, or other newer antipsychotic drugs, have not yet been explored. So to maximize the treatment of acutely exacerbated psychologically traumatizing Schizophrenia disease, scientists conducted a placebo-controlled effectiveness and safety study to compare a GlyT-1 inhibitor (Sarcosine supplement) which is an NMDA-glycine site agonist - D-serine. This was while clients received optimal risperidone therapy.
The findings indicated in the Psychological trauma symptoms of mental Schizophrenia disease that the supplement Sarcosine - when combined with risperidone - can cause synergistic benefits. And that is for negative and other psychiatric symptoms in acutely symptomatic psychological mental schizophrenia disease. In contrast, risperidone plus a Sarcosine supplemental did not differ significantly from risperidone alone in the short-term treatment. Together with recent studies, the present study suggests that using Sarcosine supplement can benefit acutely ill clients with traumatic mental schizophrenia and disability. However, Sarcosine at a dosage of 2 g/day has effectiveness only for patients with long-term stable psychological trauma symptoms of mental Schizophrenia disease.
University of Lodz Poland study A study carried out by Poland’s Medical University of Lodz has found that 6 months of use of the nutritional supplement Sarcosine (N-Methylglycine) seems to reverse the damage to the brain’s glutamate system and improves the negative and cognitive conditions (memory, concentration, social activity interest, motivation, etc. ) of people with the psychological trauma of mental Schizophrenia and disability.
This is just one of the latest of a number studies during the past decade that have shown positive effects of the supplement Sarcosine treatment of the psychological trauma of mental schizophrenia disease, and other related compounds that impact the glutamate systems, and have been shown to help people who have traumatic mental Schizophrenia and disability.
Glutamate is heavily concentrated in the hippocampus. An area of the brain thought to be significantly responsible for memory and cognition. This area, which many researchers now think may be the area whose dysfunction is the root cause of mental Schizophrenia disease. This theory is called the Glutamate Hypothesis.
This research study also reported that the supplement Sarcosine simultaneously improved mental state of clients with the Psychological trauma symptoms of mental Schizophrenia disease, as measured by the (Positive and Negative Symptoms Scale). A common measurement tool for the severity of mental Schizophrenia disease symptoms.
In summary, the researchers stated “This is the first study showing that… augmentation of the antipsychotic treatment with Sarcosine, may reverse the pathological increase in glutamatergic transmission in the hippocampus” [of people who have Schizophrenia]. Additionally, “The results confirm involvement of glutamatergic system in the pathogenesis (development) of Schizophrenia and demonstrate beneficial effects of GlyT-1 inhibitor [Sarcosine] on the metabolism in the Psychological trauma symptoms in the hippocampus and symptoms of Schizophrenia disease.
This is the first study showing that the addition to antipsychotic treatment, with the supplement Sarcosine on mental Schizophrenia for 6 months. It reveals a reverse in the harmful increase in glutamate the study will need to be duplicated by other research groups.
There is, however, already a significant amount of research completed on the role of the supplement treatment of the Psychological trauma symptoms of mental Schizophrenia disease with Sarcosine. And the related NMDA receptor co-agonists and their ability to reduce some of the negative symptoms of Psychological mental Schizophrenia disease.
Overall, the current evidence suggests that intake of 1-2 g/day of the supplement Sarcosine as adjunctive therapy to certain antipsychotic medication in mental Schizophrenia disease may have additional benefits. This is on both positive and negative symptoms of the psychological trauma of mental Schizophrenia disease. Sarcosine had been tolerated well with no notable side effects in excess of a placebo therapy.
Case report of side effects The client was a 23-year-old male suffering from the psychological trauma symptoms of mental Schizophrenia and disability for 5 years. He had undergone psychiatric hospitalization four times in the past, most recently 3 years earlier. The first episode involved a picture of typical paranoid syndrome and was induced by amphetamines. Subsequent trauma and psychotic episodes were not related to drug use. During his stable period, the client presented mild severity of negative symptoms of blunted and inappropriate affect, social withdrawal. Also, depressive disorder symptoms and moderate cognitive problems of memory and attention. These were the main indication for administration of the supplement Sarcosine to treat the psychological trauma of Schizophrenia. Among positive symptoms, the client described only periodic mild racing thoughts without typical delusions or hallucinations. Both parents had been diagnosed with mental Schizophrenia and disability. After receiving information about the supplement Sarcosine for mental Schizophrenia and disability, the client signed an informed consent form and started receiving the amino acid.
Basic laboratory tests were performed, which showed no deviation from the usual reference values. The client had no neurological, endocrine, or other chronic comorbidities at the time of undergoing treatment. The researchers excluded ongoing alcohol and drug dependence or any use in the previous 6 month, but the client did smoke around 15 cigarettes a day. Before addition of the supplement Sarcosine, the client has been receiving quetiapine 500 mg per day for 2 years and citalopram 10 mg per day for several months. Citalopram was prescribed due to panic attacks and negative symptoms.
During the first 2 weeks of the supplement Sarcosine administration at 2g a day, the client showed improvement in his overall activity, concentration, and also mood. Following a further 2 weeks of the supplement Sarcosine, he reported of a moderate inner tension with a mildly increased drive and excessive activity and irritability, a significant increase in sexual tension. Further tests ruled out any diagnosis of hypomania. The client found these conditions to be very unpleasant and asked for modification of his Sarcosine supplent treatment for his psychological trauma symptoms of mental Schizophrenia disease. There was no overall impact of side effects from the supplement Sarcosine he described as positive, and so it was decided to maintain the Sarcosine supplementation but to reduce the dosage to half as 1g a day. After lowering the dose of the supplement Sarcosine without changes in the dose of his medications, the overall intensity of his excitation and irritability decreased. The client subjectively described his overall mental health state as better in comparison with the period before Sarcosine supplementation and treatment with 2g of the amino acid. There were no external conditions that could explain his observed intensity of psychomotor agitation symptoms.
The research on whether the supplement Sarcosine and its treatment of mental Schizophrenia and disability, produces side effects seems mixed at the moment. Most studies suggest that there are no significant side effects to speak of in the use of Sarcosine supplement to treat mental Schizophrenia disease. You should also keep in mind though the fact that supplements do have different effects on different people with side effects. And they will not work exactly the same for everyone. This issue of side effects is especially true for supplements like Sarcosine that influence areas of the brain when treating the psychological trauma symptoms from mental Schizophrenia and disability.
Having said that, you may experience some general side effects from the supplement Sarcosine used for treating mental
Schizophrenia disease. Side effects of the supplement Sarcosine are usually fairly mild like headache, fatigue, and possibly nausea, and gastrointestinal discomfort. Once again, the best strategy for side effects is to take things slow and carefully observe how the Sarcosine supplement affects your body/brain barrier in its treatment of the Psychological trauma symptoms of mental Schizophrenia disease.